What Sequel Pharmaceuticals does

Sequel Pharma, LLC is a privately held specialty pharmaceutical company headquartered at 300 Interpace Parkway, Parsippany, New Jersey, that acquires, develops, and commercializes products in select therapeutic areas for the U.S. market. The firm operates a sales-led go-to-market model, distributing specialty pharmaceutical products through healthcare provider networks (hospitals, clinics, and physician practices), wholesalers, and pharmacies, rather than selling directly to consumers. Sequel Pharma employs between 11 and 50 people and is described in firmographic sources as focused on novel and clinical-stage drug candidates for cardiovascular disease, while the company's own website frames its scope more broadly as "select therapeutic areas" of specialty pharma commercialization.

The company is led by an experienced specialty-pharma management team rather than a proprietary technology platform. CEO Michael Anderson has 40+ years of pharmaceutical industry experience across branded products, generics, and medical instruments; he founded Eclat Pharmaceuticals in 2010 (sold to Flamel Technologies), then served as CEO of Flamel/Avadel Pharmaceuticals from 2012 to 2019, where the company progressed from no revenue and no profitability to a profitable specialty pharma with three approved NDAs. COO Phillandas Thompson, with an MBA and JD from the University of Michigan, spent 18 years in pharma including senior vice president, general counsel, and corporate secretary roles at Avadel Pharmaceuticals, plus legal leadership at West-Ward, Paddock, KV Pharmaceutical, and Barr Pharmaceuticals. The company does not publicly disclose a specific branded product portfolio on its website.

Sequel Pharma has raised approximately $25.4 million in disclosed equity capital across five funding events from 2007 through 2018, including a $20 million Series A in 2007 from Domain Associates, Forward Ventures, InterWest Partners, Montreux Equity Partners, and Skyline Ventures, follow-on tranches in 2009 and 2010, and a Deerfield Management relationship recorded in November 2018. The company does not publicly disclose revenue, product-level sales, pricing, or specific FDA-approved assets, and its current revenue scale and product pipeline status cannot be triangulated from public sources.

Name

Sequel Pharmaceuticals

Legal name

Sequel Pharma, LLC

Website

https://sequelpharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Sequel Pharma, LLC is a privately held, Parsippany, NJ-based specialty pharmaceutical company that acquires, develops, and commercializes products in select therapeutic areas, distributing them through U.S. healthcare providers, pharmacies, and wholesalers under experienced pharma leadership.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)

akta.pro secondary industry

Formulary Management & Clinical Pharmacy Programs (HLAEAKAA)

Keywords

• Specialty pharmaceuticals
• Cardiovascular therapeutics
• Drug commercialization
• Pharmaceutical licensing
• Clinical-stage drugs

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

1. Pharmaceutical product sales: Sequel Pharma generates revenue through the commercialization of specialty pharmaceutical products. The company acquires, develops, and markets products in select therapeutic areas, generating revenue from product sales to healthcare providers, pharmacies, and healthcare systems.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Sequel Pharma, LLC is a privately held specialty pharmaceutical company that acquires, develops, and markets pharmaceutical products in select therapeutic areas, with a focus on cardiovascular disease candidates. The company commercializes specialty drugs through healthcare provider networks, pharmacies, and healthcare systems rather than direct-to-consumer sales.

Product overview

Sequel Pharma LLC is a privately held, specialty pharmaceutical company that acquires, develops, and commercializes products in select therapeutic areas. The company operates as a single-focus specialty pharma business rather than a multi-module platform. Based in Parsippany, New Jersey, the company is led by experienced pharmaceutical executives and does not publicly list specific branded pharmaceutical products on its website. The contact page references TOPROL-XL (metoprolol succinate) in the context of a Melinta Therapeutics business inquiry, but this appears to be unrelated to Sequel Pharma's own portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• Cardiovascular Drug Candidates

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor.

• Troon Technologies LLCminorImplementation/ SI/ Consulting PartnerTroon Technologies LLC is identified as the hosting and management provider for Sequel Pharma's website and digital infrastructure. This is a technical operations support relationship rather than a core business partnership.
• Melinta TherapeuticsminorOthersMelinta Therapeutics acquired U.S. rights to TOPROL-XL® (metoprolol succinate). For medical inquiries, adverse event reporting, safety-related information, or product complaints related to TOPROL-XL, contact Melinta Medical Information at +1 844-MED-MLNT.

Recent moves5 records

Expansion highlights5 records

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sequel-pharmaceuticals-inc.

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sequel Pharmaceuticals